Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVS NASDAQ:CYCN OTCMKTS:XYNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$11.91-0.8%$13.79$3.55▼$26.95$1.01B0.841.33 million shs1.98 million shsCYCNCyclerion Therapeutics$3.20+0.6%$3.09$1.03▼$8.48$13.77M1.7828,764 shs43,760 shsXYNOXynomic Pharmaceuticals$2.22$2.22$0.20▼$3.84N/AN/AN/AN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals-0.75%+2.39%+3.57%-10.65%+203.05%CYCNCyclerion Therapeutics+0.63%-0.31%+6.67%+101.26%+1.59%XYNOXynomic Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$11.91-0.8%$13.79$3.55▼$26.95$1.01B0.841.33 million shs1.98 million shsCYCNCyclerion Therapeutics$3.20+0.6%$3.09$1.03▼$8.48$13.77M1.7828,764 shs43,760 shsXYNOXynomic Pharmaceuticals$2.22$2.22$0.20▼$3.84N/AN/AN/AN/A7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals-0.75%+2.39%+3.57%-10.65%+203.05%CYCNCyclerion Therapeutics+0.63%-0.31%+6.67%+101.26%+1.59%XYNOXynomic Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 2.71Moderate Buy$33.33179.88% UpsideCYCNCyclerion Therapeutics 1.00SellN/AN/AXYNOXynomic Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CRVS, CYCN, and XYNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026CRVSCorvus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026CYCNCyclerion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/17/2026CRVSCorvus Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.004/17/2026CRVSCorvus Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/A$0.13 per share94.67$0.73 per shareN/ACYCNCyclerion Therapeutics$2.07M6.69N/AN/A$2.31 per share1.39XYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$15.28M-$0.52N/AN/AN/AN/A-38.92%-35.75%8/6/2026 (Estimated)CYCNCyclerion Therapeutics-$3.53M-$1.36N/AN/AN/A-170.11%-62.10%-55.14%8/4/2026 (Estimated)XYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest CRVS, CYCN, and XYNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CYCNCyclerion Therapeutics-$17.20-$0.76+$16.44-$0.76$0.88 millionN/A5/7/2026Q1 2026CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/A3/30/2026Q4 2025CYCNCyclerion Therapeutics-$0.38-$0.19+$0.19-$0.19$0.10 million$1.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A19.8119.81CYCNCyclerion TherapeuticsN/A1.801.80XYNOXynomic PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%CYCNCyclerion Therapeutics75.62%XYNOXynomic PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals19.70%CYCNCyclerion Therapeutics34.30%XYNOXynomic Pharmaceuticals86.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3084.09 million67.52 millionOptionableCYCNCyclerion Therapeutics304.33 million2.85 millionNo DataXYNOXynomic Pharmaceuticals27N/AN/ANot OptionableCRVS, CYCN, and XYNO HeadlinesRecent News About These CompaniesIndolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsightOctober 16, 2025 | finance.yahoo.comHDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsightAugust 20, 2025 | prnewswire.co.ukPindian cricket team t20 world cupDecember 28, 2024 | bwhotelier.businessworld.inBFollicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightNovember 29, 2024 | finance.yahoo.comAbexinostat by Xynomic Pharmaceuticals for Follicular Lymphoma: Likelihood of ApprovalSeptember 10, 2024 | pharmaceutical-technology.comPAbexinostat by Xynomic Pharmaceuticals for High-Grade Glioma: Likelihood of ApprovalSeptember 9, 2024 | pharmaceutical-technology.comPAbexinostat by Xynomic Pharmaceuticals for Anaplastic Astrocytoma: Likelihood of ApprovalSeptember 9, 2024 | pharmaceutical-technology.comPGame-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsightAugust 6, 2024 | finance.yahoo.comAbexinostat by Xynomic Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of ApprovalMay 17, 2024 | pharmaceutical-technology.comPFull-Time MBA concentration in Pharmaceutical ManagementApril 28, 2024 | business.rutgers.eduBGlioblastoma Pipeline Landscape Report 2024: Pivotal Advances in Treatment Protocols and Drug DevelopmentsApril 26, 2024 | finance.yahoo.comNon-Hodgkin Lymphoma Pipeline Landscape 2024: Analysis of Over 220 Potential Pharmaceuticals in DevelopmentApril 25, 2024 | finance.yahoo.comWatson PharmaceuticalsFebruary 21, 2024 | forbes.comElite Pharmaceuticals Inc.February 14, 2024 | wsj.comHDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJanuary 8, 2024 | finance.yahoo.comFennec Pharmaceuticals Inc FENCNovember 1, 2023 | morningstar.comMStarfield:PharmaceuticalsSeptember 26, 2023 | videogamer.comVDelveInsight Highlights Major Advances, Transformative Therapies, and 195+ Leading Players Wheeling the Glioblastoma Clinical Trial Pipeline LandscapeSeptember 1, 2023 | benzinga.comGlaxosmithkline PharmaceuticalsJuly 8, 2023 | livemint.comCompany History - Paam PharmaceuticalsMay 30, 2023 | moneycontrol.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVS, CYCN, and XYNO Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$11.91 -0.09 (-0.75%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$12.15 +0.24 (+2.01%) As of 06/18/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Cyclerion Therapeutics NASDAQ:CYCN$3.20 +0.02 (+0.63%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.08 -0.13 (-3.91%) As of 06/18/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Xynomic Pharmaceuticals OTCMKTS:XYNO$2.22 0.00 (0.00%) As of 06/23/2021Xynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
